The agency took the unusual step based on what it called a severely lacking response by sheriff’s deputies to Keith Galen ...

I did the insulin, and it kicked in ... He said he built 571 miles of border wall. Official government statistics show it was ...

“I just ate so many cupcakes, I got diabetes,” a co-worker joked from across the cubicle wall. Another group of coworkers erupted in laughter. While the joke may have seemed harmless to ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 586.36% and ...

Cigna and CVS Health — the three largest pharmacy-benefit managers — over their tactics for negotiating prices for drugs ...

Cardiovascular conditions like coronary artery disease, congenital heart disorders, and abnormal heartbeats can cause you to ...

Wall Street analysts can barely keep up with the pace of the diabetes and weight loss drug markets – and for good reason. Thanks to ample customer demand, production increases and an improving ...

Hims & Hers Health (HIMS 5.09%) has built its brand up in recent years by focusing on offering its customers products related ...

Adjusted earnings per share came in at $3.92, which also beat Wall Street estimates of $2.60 per share. Lilly's tirzepatide was first approved to treat type 2 diabetes and sold under the brand ...

Wall Street analysts are betting on a 2027 list that will include Novo Nordisk's blockbuster (NOVOb.CO), opens new tab Ozempic for diabetes and have a limited impact on Big Pharma. The drugs ...

Insulet (PODD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Patrick Wood ...